查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1950518

按设备类型、技术和最终用途分類的全球卵子收集设备市场预测（2026-2032年）

Oocyte Collectors Market by Collector Type, Technology, End Use - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 188 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2025年卵子收集设备市场价值为2,931万美元，预计到2026年将成长至3,275万美元，年复合成长率为4.61%，到2032年将达到4019万美元。

关键市场统计数据
基准年 2025 2931万美元
预计年份：2026年 3275万美元
预测年份 2032 4019万美元
复合年增长率 (%) 4.61%

权威的卵子采集设备指南，说明了临床应用、设备类别、相关人员的优先事项，以及这些因素如何影响采购决策。

卵子采集装置在辅助生殖中发挥核心作用，连接着不孕症、医院和研究环境中的临床和医疗设备工程。这些装置能够实现精准的卵子采集，减少操作差异，并提高检体完整性。因此，它们很容易受到临床医生偏好变化、灭菌通讯协定演变以及自动化技术进步的影响。本介绍将阐明临床背景，定义装置类型，并指出影响采购和实施决策的关键相关人员。

技术创新、灭菌标准和系统级整合如何重塑卵子采集实务中的产品开发和临床应用

受技术创新、日益严格的感染防治法规以及医疗机构采购政策变化的影响，卵子采集设备的市场格局正经历多重变革。自动化程度的提高正在重新定义使用者的期望，可程式设计的工作流程，从而提高抽吸模式的一致性并减少操作人员的差异。同时，对灭菌化学和可重复使用设备生命週期管理的日益重视，迫使製造商重新思考材料和服务模式，并透过耐用性和检验的清洁流程创造新的差异化机会。

美国近期加征关税对卵子收集设备相关人员的采购、製造地、筹资策略和供应链韧性的影响

美国近期关税调整正在改变医疗设备供应链的成本结构，对卵子采集设备製造商、经销商和终端用户都产生了实际的影响。关税影响采购、零件在地采购和库存策略的决策，促使一些供应商重新评估其供应组合併探索其他製造地。因此，采购机构面临对到岸成本、前置作业时间和供应商韧性的更严格审查，这影响合约谈判和资本规划。

将采集器类型、自动化程度和最终使用环境与购买行为、临床工作流程和商业化策略连结起来的精确細項分析

对市场区隔的详细分析揭示了设备设计、自动化程度和使用环境将如何影响采购优先顺序和市场接受度曲线。根据收集器类型，市场可分为一次性使用和可重复使用两类。可重复使用产品可进一步分为高压釜及化学灭菌型。这种区分至关重要，因为一次性解决方案强调一次性使用的无菌性和简化的物流，而可重复使用方案则以较低的前期资本投入和更复杂的灭菌流程为代价，换取了更低的单次手术材料成本和潜在的废物排放减少。製造商和医疗系统在选择这些方案时，必须考虑生命週期通讯协定、灭菌验证和材料相容性。

区域需求模式和监管差异决定了美洲、欧洲、中东和非洲以及亚太地区的市场进入和商业化策略的差异化。

区域趋势造就了不同的需求驱动因素和应用模式，反映了当地的临床基础设施、法规结构和采购重点。在美洲，应用主要集中在专业的生育中心和综合医院系统，买家关注设备的可靠性、灭菌能力和供应商的应对力。欧洲、中东和非洲地区的市场结构较为复杂，有些国家拥有完善的管理体制，而有些国家的辅助生殖基础设施则相对欠发达，这为灵活的产品供应和分级支援模式创造了机会。亚太地区涵盖了广泛的临床环境和快速增长的生育服务，因此，扩充性、成本效益和本地化生产伙伴关係对于市场准入和扩张至关重要。

由产品创新、临床检验、服务生态系统和策略联盟驱动的竞争格局将决定产品在临床环境中的采用和保留。

卵子采集领域的竞争格局取决于设备创新、服务生态系统和临床可靠性之间的平衡。领先的製造商透过投资可用性研究、灭菌检验和整合能力，建立临床信任并与高运作的医疗机构建立长期合作关係。新参与企业通常透过追求细分市场差异化来站稳脚跟，例如低成本的一次性产品、先进的自动化模组和易于灭菌的材料；而现有供应商则利用其成熟的分销网络和临床证据来捍卫市场份额，并向综合生殖健康产品组合进行交叉销售。

针对製造商和经销商的高影响力策略行动，旨在加速设备采用、降低供应链风险并建立可防御的竞争优势。

产业领导者应采取一系列切实可行的措施，以巩固市场地位、推动产品普及并降低外部风险。首先，应优先考虑模组化产品架构和检验的灭菌途径，并设计可相容于一次性使用和可重复使用工作流程的设备，以满足多样化的客户需求，同时简化监管申报流程。其次，应投资于自动化能力，以提高操作的可重复性并降低对操作人员的依赖性，同时辅以完善的培训模组和模拟程序，以缩短临床医生的学习曲线。

该研究透过透明的多来源调查方法检验了研究结果，该方法结合了临床环境中的面对面访谈、程序观察和严格的文献综述。

本研究结合一手资料和二手资料，全面涵盖了临床、技术和商业性方面。一手资料包括对临床医生、采购经理和医疗设备技术人员进行结构化访谈，以及与消毒专业人员和检查室管理人员进行面对面交流，以了解操作流程。此外，还对典型的生育诊所和检查室环境中的手术流程和设备操作进行了观察性研究，以检验使用者体验和培训需求。

综合各项策略需求表明，检验的灭菌流程、自动化实施以及区域一致性将决定未来的临床和商业性成功。

总之，卵子采集设备的市场环境将由临床需求、灭菌需求、自动化进展、区域性采购模式等因素交互作用决定。那些能够使产品设计与检验的灭菌流程相匹配、投资于可重复的自动化技术并采取符合区域特征的商业性相关人员的利益相关者，将最有利于赢得临床信任并实现长期市场应用。同时，供应链的韧性以及积极应对关税造成的成本波动策略对于保护利润和维持服务水准至关重要。

目录

第一章：序言

第二章调查方法

  • 研究设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查前提
  • 调查限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会地图
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 按收集器类型分類的卵子收集设备市场

  • 一次性
  • 可重复使用的
    • 高压釜灭菌
    • 化学可灭菌

第九章卵子器市场：依技术分类

  • 自动的
  • 手动的
  • 半自动

第十章卵子设备市场：依最终用途划分

  • 不孕不育诊所
  • 医院
  • 研究所

第十一章卵子收集装置市场：依地区划分

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十二章卵子收集设备市场（依类别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十三章 各国卵子收集设备市场

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十四章：美国卵子收集设备市场

第十五章 中国集卵子设备市场

第十六章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Boston IVF, Inc.
  • CARE Fertility Group Limited
  • Colorado Center for Reproductive Medicine, LLC
  • Corning Incorporated
  • Eppendorf AG
  • Fertility Partners, Inc.
  • Genea Biomedx Pty Ltd
  • Gynotec BV
  • IMV Technologies
  • IVFtech ApS
  • IVI RMA Global SL
  • Kitazato Corporation
  • Labotect GmbH
  • Monash IVF Group Limited
  • Nidacon International AB
  • Nikon Corporation
  • Olympus Corporation
  • PHC Holdings Corporation
  • Reprofit International as
  • Rocket Medical plc
  • Shady Grove Fertility Center, LLC
  • Smiths Medical（Smiths Group plc）
  • Sysmex Corporation
  • Terumo Corporation
  • The Baker Company, Inc.
  • Virtus Health Limited
Product Code: MRR-4F7A6D4FD8B5

The Oocyte Collectors Market was valued at USD 29.31 million in 2025 and is projected to grow to USD 32.75 million in 2026, with a CAGR of 4.61%, reaching USD 40.19 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 29.31 million
Estimated Year [2026] USD 32.75 million
Forecast Year [2032] USD 40.19 million
CAGR (%) 4.61%

An authoritative orientation to oocyte collectors describing clinical roles, device categories, stakeholder priorities, and how these elements converge to shape procurement decisions

Oocyte collectors are central to assisted reproductive procedures, and their function bridges clinical technique and device engineering in fertility, hospital, and research settings. The devices enable precise retrieval of oocytes, reducing procedural variability and improving specimen integrity; as such, they are subject to evolving clinician preferences, sterilization protocols, and automation advances. This introduction establishes the clinical context, clarifies device typologies, and identifies the principal stakeholders who influence procurement and adoption decisions.

Clinicians prioritize reliability and ease of use during transvaginal oocyte retrieval, which drives demand for devices that offer consistent suction control, minimal trauma, and compatibility with existing assisted reproductive workflows. Concurrently, medical device engineers focus on materials, sterilization compatibility, and control systems that balance disposability and reusability. Health systems evaluate devices through the lens of operational efficiency, infection control, and total cost of ownership, linking procurement decisions to procedural volumes and regulatory compliance. Taken together, these forces create a dynamic landscape that requires nuanced understanding of device characteristics, clinical outcomes, and institutional constraints.

How technological innovation, sterilization standards, and system-level integration are redirecting product development and clinical adoption across oocyte collection practice

The landscape for oocyte collectors is undergoing several transformative shifts driven by technology, regulatory emphasis on infection prevention, and changing institutional procurement philosophies. Advances in automation are reshaping user expectations, enabling more consistent suction profiles and programmable workflows that reduce operator variability. At the same time, heightened attention to sterilization chemistry and reusable device lifecycle management has pushed manufacturers to rethink materials and service models, creating new opportunities for differentiation through durability and validated cleaning processes.

Additionally, integration of digital controls and modular interfaces is facilitating compatibility with broader laboratory information systems, which enhances traceability and quality assurance. These technological shifts are complemented by procedural trends: clinicians increasingly favor devices that reduce procedural time, improve specimen quality, and integrate seamlessly into assisted reproductive technology suites. As a result, manufacturers and clinical leaders must collaborate to align product roadmaps with evolving clinical protocols, ensuring both regulatory compliance and adoption in high-volume centers. In short, the sector's trajectory combines device innovation with a systems-level focus on sterility, repeatability, and digital interoperability.

Implications of recent United States tariffs on sourcing, manufacturing footprints, procurement strategies, and supply chain resilience for oocyte collector stakeholders

Recent tariff changes in the United States have altered cost dynamics across medical device supply chains, with tangible implications for manufacturers, distributors, and end users of oocyte collectors. Tariffs influence decisions about sourcing, component localization, and inventory strategy, prompting some suppliers to reassess supplier portfolios and seek alternative manufacturing bases. Consequently, organizations engaged in procurement face heightened scrutiny over landed costs, lead times, and supplier resilience, which in turn affects contract negotiations and capital planning.

In practical terms, procurement teams are prioritizing suppliers with diversified manufacturing footprints or established domestic production to mitigate tariff exposure and supply chain disruption. Meanwhile, manufacturers with global operations are accelerating localization of critical components or exploring tariff engineering strategies to minimize cost impacts. For clinical programs and research institutions, the immediate effect is more rigorous vendor evaluation and an increased willingness to consider total lifecycle costs rather than purchase price alone. As policy and trade environments continue to evolve, stakeholders must remain agile, updating sourcing strategies and contingency plans to preserve operational continuity and manage budgetary pressures.

Precise segmentation analysis linking collector type, automation tiers, and end-use environments to purchasing behavior, clinical workflows, and commercialization strategies

A granular view of segmentation reveals how device design, automation level, and use environment shape procurement priorities and adoption curves. Based on Collector Type, market is studied across Disposable and Reusable. The Reusable is further studied across Autoclavable and Chemical Sterilizable. This distinction matters because disposable solutions emphasize single-use sterility and simplified logistics, whereas reusable options trade higher upfront capital and sterilization workflows for lower per-procedure material expenditure and potentially reduced waste streams. Manufacturers and health systems must consider lifecycle protocols, sterilization validation, and material compatibility when selecting between these approaches.

Based on Technology, market is studied across Automatic, Manual, and Semi Automatic. The Automatic is further studied across Programmable and Robotic. The Manual is further studied across Capillary Tube and Suction Pump. The Semi Automatic is further studied across Air Pressure System and Electric Suction. Technology segmentation captures a spectrum from clinician-operated simplicity to fully automated systems that embed programmable parameters or robotic precision. Manual devices retain advantages in cost and familiarity, particularly in lower-volume settings, while automatic and semi-automatic options appeal to high-volume clinics seeking consistency, reduced operator fatigue, and integration with electronic recordkeeping. Robotic and programmable systems introduce higher capital and training demands but offer reproducibility that can standardize outcomes across operators.

Based on End Use, market is studied across Fertility Clinic, Hospital, and Research Institute. End-user segmentation underscores divergent purchasing criteria: fertility clinics often prioritize throughput, patient experience, and clinic-specific workflow integration; hospitals may emphasize cross-department utility, sterilization standards, and procurement policy alignment; research institutes place premium value on experimental flexibility, data capture capabilities, and compatibility with specialized laboratory equipment. Collectively, these segmentation lenses inform commercialization strategies, shaping pricing models, service offerings, and clinical support programs. As a result, vendors must craft differentiated value propositions that address sterilization pathways, automation preferences, and the specific procedural demands of each end-use environment.

Regional demand patterns and regulatory nuances across the Americas, Europe Middle East & Africa, and Asia-Pacific that dictate differentiated market entry and commercialization strategies

Regional dynamics create divergent demand drivers and adoption patterns that reflect local clinical infrastructures, regulatory frameworks, and procurement priorities. Americas exhibit concentrated adoption in specialized fertility centers and integrated hospital systems, with buyer attention on device reliability, sterilization throughput, and supplier responsiveness. Europe, Middle East & Africa show heterogenous markets where established regulatory regimes in some countries coexist with nascent assisted reproductive infrastructure in others, creating opportunities for flexible product offerings and tiered support models. Asia-Pacific encompasses a wide spectrum of clinical environments and rapidly growing fertility services, where scalability, cost-efficiency, and local manufacturing partnerships are major influences on market entry and expansion.

These geographic distinctions shape go-to-market approaches: in the Americas, emphasis on value-added services and clinical validation studies strengthens clinical adoption; across Europe, Middle East & Africa, regulatory navigation and tailored training programs determine pace of uptake; and in Asia-Pacific, strategic alliances with local distributors and manufacturing localization can significantly accelerate penetration. Understanding these regional nuances enables manufacturers and suppliers to prioritize deployments, align training and after-sales support, and adapt product features to meet distinct clinical and regulatory expectations.

Competitive dynamics driven by product innovation, clinical validation, service ecosystems, and strategic partnerships that determine adoption and retention in clinical settings

Competitive dynamics in the oocyte collectors domain are defined by a balance between device innovation, service ecosystems, and clinical credibility. Leading manufacturers invest in usability research, sterilization validation, and integration capabilities to establish clinical trust and long-term relationships with high-volume centers. New entrants often pursue niche differentiation-such as low-cost disposables, advanced automation modules, or sterilization-friendly materials-to gain an initial foothold, while incumbent suppliers leverage established distribution networks and clinical evidence to defend share and cross-sell to integrated reproductive health portfolios.

Partnerships with clinical opinion leaders and participation in multicenter procedural studies amplify product credibility and accelerate adoption, particularly for automated or semi-automated platforms that require changes in clinician technique. Meanwhile, aftermarket service and device maintenance programs influence purchasing decisions, as institutions weigh the benefits of warranty, rapid parts replacement, and training against capital expenditures. Ultimately, the competitive landscape rewards firms that combine technical robustness with comprehensive clinical support and clear evidence of improved procedural consistency or operational efficiency.

High-impact strategic actions for manufacturers and distributors to enhance device adoption, mitigate supply chain risk, and build defensible competitive differentiation

Industry leaders should adopt a set of actionable measures to secure market position, accelerate adoption, and mitigate external risks. First, prioritize modular product architectures and validated sterilization pathways so that devices can be configured for disposable or reusable workflows, meeting diverse customer requirements and simplifying regulatory submissions. Second, invest in automation features that improve reproducibility and reduce operator dependency, accompanied by robust training modules and simulation programs to shorten the clinician learning curve.

Third, diversify supply chains and consider selective localization of critical components to reduce exposure to tariff volatility and to shorten lead times. Fourth, strengthen clinical evidence through prospective usability and outcomes studies, focusing on metrics that matter to purchasers such as procedure time, specimen integrity, and reprocessing efficiency. Fifth, tailor commercial strategies by end-user segment and region, offering flexible pricing, leasing options, and bundled service agreements that align with procurement policies. By executing these priorities in a coordinated manner, manufacturers and distributors can enhance resilience, deepen clinical partnerships, and create defensible differentiation in a competitive landscape.

A transparent, multi-source research methodology combining firsthand clinical interviews, procedural observations, and rigorous literature review to validate insights

This research synthesizes primary and secondary inquiries to ensure comprehensive coverage of clinical, technical, and commercial dimensions. Primary inputs included structured interviews with practicing clinicians, procurement leaders, and device engineers, as well as direct consultations with sterilization specialists and laboratory managers to capture operational realities. These qualitative discussions were complemented by observational reviews of procedural workflows and device handling in representative fertility clinics and laboratory settings to validate user experience and training needs.

Secondary research encompassed peer-reviewed literature, regulatory guidance documents, device standards, and published clinical studies relevant to oocyte retrieval procedures and device sterilization. Data triangulation combined these multiple sources to identify consistent themes and reconcile divergent findings. Throughout the process, emphasis was placed on transparency in methodology, clear attribution of data sources, and iterative validation with subject-matter experts to ensure conclusions are both robust and actionable for decision-makers.

Synthesis of strategic imperatives showing how validated sterilization, automation adoption, and regional alignment will determine future clinical and commercial success

In closing, the oocyte collectors landscape is defined by the interplay of clinical requirements, sterilization imperatives, automation trajectories, and region-specific procurement patterns. Stakeholders who align product design with validated sterilization workflows, invest in reproducible automation, and adapt commercial approaches to regional nuances will be best positioned to capture clinical trust and long-term adoption. Concurrently, supply chain resilience and proactive strategies to manage tariff-driven cost dynamics are essential to protect margins and sustain service levels.

Moving forward, decision-makers should prioritize collaborations between clinical teams and product developers to co-create devices that fit procedural realities while delivering measurable improvements in consistency and efficiency. By focusing on validated performance, streamlined reprocessing, and flexible commercial models, manufacturers and health systems can drive improved outcomes and operational efficiency, ensuring that device advancement translates into tangible clinical benefit.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Oocyte Collectors Market, by Collector Type

  • 8.1. Disposable
  • 8.2. Reusable
    • 8.2.1. Autoclavable
    • 8.2.2. Chemical Sterilizable

9. Oocyte Collectors Market, by Technology

  • 9.1. Automatic
  • 9.2. Manual
  • 9.3. Semi Automatic

10. Oocyte Collectors Market, by End Use

  • 10.1. Fertility Clinic
  • 10.2. Hospital
  • 10.3. Research Institute

11. Oocyte Collectors Market, by Region

  • 11.1. Americas
    • 11.1.1. North America
    • 11.1.2. Latin America
  • 11.2. Europe, Middle East & Africa
    • 11.2.1. Europe
    • 11.2.2. Middle East
    • 11.2.3. Africa
  • 11.3. Asia-Pacific

12. Oocyte Collectors Market, by Group

  • 12.1. ASEAN
  • 12.2. GCC
  • 12.3. European Union
  • 12.4. BRICS
  • 12.5. G7
  • 12.6. NATO

13. Oocyte Collectors Market, by Country

  • 13.1. United States
  • 13.2. Canada
  • 13.3. Mexico
  • 13.4. Brazil
  • 13.5. United Kingdom
  • 13.6. Germany
  • 13.7. France
  • 13.8. Russia
  • 13.9. Italy
  • 13.10. Spain
  • 13.11. China
  • 13.12. India
  • 13.13. Japan
  • 13.14. Australia
  • 13.15. South Korea

14. United States Oocyte Collectors Market

15. China Oocyte Collectors Market

16. Competitive Landscape

  • 16.1. Market Concentration Analysis, 2025
    • 16.1.1. Concentration Ratio (CR)
    • 16.1.2. Herfindahl Hirschman Index (HHI)
  • 16.2. Recent Developments & Impact Analysis, 2025
  • 16.3. Product Portfolio Analysis, 2025
  • 16.4. Benchmarking Analysis, 2025
  • 16.5. Boston IVF, Inc.
  • 16.6. CARE Fertility Group Limited
  • 16.7. Colorado Center for Reproductive Medicine, LLC
  • 16.8. Corning Incorporated
  • 16.9. Eppendorf AG
  • 16.10. Fertility Partners, Inc.
  • 16.11. Genea Biomedx Pty Ltd
  • 16.12. Gynotec B.V.
  • 16.13. IMV Technologies
  • 16.14. IVFtech ApS
  • 16.15. IVI RMA Global S.L.
  • 16.16. Kitazato Corporation
  • 16.17. Labotect GmbH
  • 16.18. Monash IVF Group Limited
  • 16.19. Nidacon International AB
  • 16.20. Nikon Corporation
  • 16.21. Olympus Corporation
  • 16.22. PHC Holdings Corporation
  • 16.23. Reprofit International a.s.
  • 16.24. Rocket Medical plc
  • 16.25. Shady Grove Fertility Center, LLC
  • 16.26. Smiths Medical (Smiths Group plc)
  • 16.27. Sysmex Corporation
  • 16.28. Terumo Corporation
  • 16.29. The Baker Company, Inc.
  • 16.30. Virtus Health Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL OOCYTE COLLECTORS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL OOCYTE COLLECTORS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL OOCYTE COLLECTORS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL OOCYTE COLLECTORS MARKET SIZE, BY COLLECTOR TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL OOCYTE COLLECTORS MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL OOCYTE COLLECTORS MARKET SIZE, BY END USE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL OOCYTE COLLECTORS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL OOCYTE COLLECTORS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL OOCYTE COLLECTORS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. UNITED STATES OOCYTE COLLECTORS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 11. CHINA OOCYTE COLLECTORS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL OOCYTE COLLECTORS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL OOCYTE COLLECTORS MARKET SIZE, BY COLLECTOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL OOCYTE COLLECTORS MARKET SIZE, BY DISPOSABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL OOCYTE COLLECTORS MARKET SIZE, BY DISPOSABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL OOCYTE COLLECTORS MARKET SIZE, BY DISPOSABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL OOCYTE COLLECTORS MARKET SIZE, BY REUSABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL OOCYTE COLLECTORS MARKET SIZE, BY REUSABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL OOCYTE COLLECTORS MARKET SIZE, BY REUSABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL OOCYTE COLLECTORS MARKET SIZE, BY REUSABLE, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL OOCYTE COLLECTORS MARKET SIZE, BY AUTOCLAVABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL OOCYTE COLLECTORS MARKET SIZE, BY AUTOCLAVABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL OOCYTE COLLECTORS MARKET SIZE, BY AUTOCLAVABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL OOCYTE COLLECTORS MARKET SIZE, BY CHEMICAL STERILIZABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL OOCYTE COLLECTORS MARKET SIZE, BY CHEMICAL STERILIZABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL OOCYTE COLLECTORS MARKET SIZE, BY CHEMICAL STERILIZABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL OOCYTE COLLECTORS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL OOCYTE COLLECTORS MARKET SIZE, BY AUTOMATIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL OOCYTE COLLECTORS MARKET SIZE, BY AUTOMATIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL OOCYTE COLLECTORS MARKET SIZE, BY AUTOMATIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL OOCYTE COLLECTORS MARKET SIZE, BY MANUAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL OOCYTE COLLECTORS MARKET SIZE, BY MANUAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL OOCYTE COLLECTORS MARKET SIZE, BY MANUAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL OOCYTE COLLECTORS MARKET SIZE, BY SEMI AUTOMATIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL OOCYTE COLLECTORS MARKET SIZE, BY SEMI AUTOMATIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL OOCYTE COLLECTORS MARKET SIZE, BY SEMI AUTOMATIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL OOCYTE COLLECTORS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL OOCYTE COLLECTORS MARKET SIZE, BY FERTILITY CLINIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL OOCYTE COLLECTORS MARKET SIZE, BY FERTILITY CLINIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL OOCYTE COLLECTORS MARKET SIZE, BY FERTILITY CLINIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL OOCYTE COLLECTORS MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL OOCYTE COLLECTORS MARKET SIZE, BY HOSPITAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL OOCYTE COLLECTORS MARKET SIZE, BY HOSPITAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL OOCYTE COLLECTORS MARKET SIZE, BY RESEARCH INSTITUTE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL OOCYTE COLLECTORS MARKET SIZE, BY RESEARCH INSTITUTE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL OOCYTE COLLECTORS MARKET SIZE, BY RESEARCH INSTITUTE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL OOCYTE COLLECTORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. AMERICAS OOCYTE COLLECTORS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 38. AMERICAS OOCYTE COLLECTORS MARKET SIZE, BY COLLECTOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 39. AMERICAS OOCYTE COLLECTORS MARKET SIZE, BY REUSABLE, 2018-2032 (USD MILLION)
  • TABLE 40. AMERICAS OOCYTE COLLECTORS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 41. AMERICAS OOCYTE COLLECTORS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 42. NORTH AMERICA OOCYTE COLLECTORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. NORTH AMERICA OOCYTE COLLECTORS MARKET SIZE, BY COLLECTOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 44. NORTH AMERICA OOCYTE COLLECTORS MARKET SIZE, BY REUSABLE, 2018-2032 (USD MILLION)
  • TABLE 45. NORTH AMERICA OOCYTE COLLECTORS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 46. NORTH AMERICA OOCYTE COLLECTORS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 47. LATIN AMERICA OOCYTE COLLECTORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. LATIN AMERICA OOCYTE COLLECTORS MARKET SIZE, BY COLLECTOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 49. LATIN AMERICA OOCYTE COLLECTORS MARKET SIZE, BY REUSABLE, 2018-2032 (USD MILLION)
  • TABLE 50. LATIN AMERICA OOCYTE COLLECTORS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 51. LATIN AMERICA OOCYTE COLLECTORS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 52. EUROPE, MIDDLE EAST & AFRICA OOCYTE COLLECTORS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 53. EUROPE, MIDDLE EAST & AFRICA OOCYTE COLLECTORS MARKET SIZE, BY COLLECTOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 54. EUROPE, MIDDLE EAST & AFRICA OOCYTE COLLECTORS MARKET SIZE, BY REUSABLE, 2018-2032 (USD MILLION)
  • TABLE 55. EUROPE, MIDDLE EAST & AFRICA OOCYTE COLLECTORS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 56. EUROPE, MIDDLE EAST & AFRICA OOCYTE COLLECTORS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 57. EUROPE OOCYTE COLLECTORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. EUROPE OOCYTE COLLECTORS MARKET SIZE, BY COLLECTOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 59. EUROPE OOCYTE COLLECTORS MARKET SIZE, BY REUSABLE, 2018-2032 (USD MILLION)
  • TABLE 60. EUROPE OOCYTE COLLECTORS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 61. EUROPE OOCYTE COLLECTORS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 62. MIDDLE EAST OOCYTE COLLECTORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. MIDDLE EAST OOCYTE COLLECTORS MARKET SIZE, BY COLLECTOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 64. MIDDLE EAST OOCYTE COLLECTORS MARKET SIZE, BY REUSABLE, 2018-2032 (USD MILLION)
  • TABLE 65. MIDDLE EAST OOCYTE COLLECTORS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 66. MIDDLE EAST OOCYTE COLLECTORS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 67. AFRICA OOCYTE COLLECTORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. AFRICA OOCYTE COLLECTORS MARKET SIZE, BY COLLECTOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 69. AFRICA OOCYTE COLLECTORS MARKET SIZE, BY REUSABLE, 2018-2032 (USD MILLION)
  • TABLE 70. AFRICA OOCYTE COLLECTORS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 71. AFRICA OOCYTE COLLECTORS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 72. ASIA-PACIFIC OOCYTE COLLECTORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. ASIA-PACIFIC OOCYTE COLLECTORS MARKET SIZE, BY COLLECTOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 74. ASIA-PACIFIC OOCYTE COLLECTORS MARKET SIZE, BY REUSABLE, 2018-2032 (USD MILLION)
  • TABLE 75. ASIA-PACIFIC OOCYTE COLLECTORS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 76. ASIA-PACIFIC OOCYTE COLLECTORS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL OOCYTE COLLECTORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. ASEAN OOCYTE COLLECTORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. ASEAN OOCYTE COLLECTORS MARKET SIZE, BY COLLECTOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 80. ASEAN OOCYTE COLLECTORS MARKET SIZE, BY REUSABLE, 2018-2032 (USD MILLION)
  • TABLE 81. ASEAN OOCYTE COLLECTORS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 82. ASEAN OOCYTE COLLECTORS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 83. GCC OOCYTE COLLECTORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GCC OOCYTE COLLECTORS MARKET SIZE, BY COLLECTOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 85. GCC OOCYTE COLLECTORS MARKET SIZE, BY REUSABLE, 2018-2032 (USD MILLION)
  • TABLE 86. GCC OOCYTE COLLECTORS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 87. GCC OOCYTE COLLECTORS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 88. EUROPEAN UNION OOCYTE COLLECTORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. EUROPEAN UNION OOCYTE COLLECTORS MARKET SIZE, BY COLLECTOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 90. EUROPEAN UNION OOCYTE COLLECTORS MARKET SIZE, BY REUSABLE, 2018-2032 (USD MILLION)
  • TABLE 91. EUROPEAN UNION OOCYTE COLLECTORS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 92. EUROPEAN UNION OOCYTE COLLECTORS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 93. BRICS OOCYTE COLLECTORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. BRICS OOCYTE COLLECTORS MARKET SIZE, BY COLLECTOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 95. BRICS OOCYTE COLLECTORS MARKET SIZE, BY REUSABLE, 2018-2032 (USD MILLION)
  • TABLE 96. BRICS OOCYTE COLLECTORS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 97. BRICS OOCYTE COLLECTORS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 98. G7 OOCYTE COLLECTORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. G7 OOCYTE COLLECTORS MARKET SIZE, BY COLLECTOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 100. G7 OOCYTE COLLECTORS MARKET SIZE, BY REUSABLE, 2018-2032 (USD MILLION)
  • TABLE 101. G7 OOCYTE COLLECTORS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 102. G7 OOCYTE COLLECTORS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 103. NATO OOCYTE COLLECTORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. NATO OOCYTE COLLECTORS MARKET SIZE, BY COLLECTOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 105. NATO OOCYTE COLLECTORS MARKET SIZE, BY REUSABLE, 2018-2032 (USD MILLION)
  • TABLE 106. NATO OOCYTE COLLECTORS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 107. NATO OOCYTE COLLECTORS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL OOCYTE COLLECTORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. UNITED STATES OOCYTE COLLECTORS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 110. UNITED STATES OOCYTE COLLECTORS MARKET SIZE, BY COLLECTOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 111. UNITED STATES OOCYTE COLLECTORS MARKET SIZE, BY REUSABLE, 2018-2032 (USD MILLION)
  • TABLE 112. UNITED STATES OOCYTE COLLECTORS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 113. UNITED STATES OOCYTE COLLECTORS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 114. CHINA OOCYTE COLLECTORS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 115. CHINA OOCYTE COLLECTORS MARKET SIZE, BY COLLECTOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 116. CHINA OOCYTE COLLECTORS MARKET SIZE, BY REUSABLE, 2018-2032 (USD MILLION)
  • TABLE 117. CHINA OOCYTE COLLECTORS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 118. CHINA OOCYTE COLLECTORS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)